News|Videos|December 4, 2023
Expanding Horizons in Endometrial Cancer Treatment: Beyond Chemotherapy
Author(s)Ritu Salani, MD, Bhavana Pothuri, MD
Delve into the exciting developments in endometrial cancer treatment, including HER2 antibody drug conjugates, checkpoint inhibitors, and the promising impact of these therapies in the quest to reduce chemotherapy use.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts convened to discuss ADC sequencing strategies, biomarker testing infrastructure, and emerging data across cervical, ovarian, and endometrial cancers.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus Lenalidomide/Rituximab Win EU Approval for R/R Follicular Lymphoma
2
Adagrasib Plus Cetuximab Misses OS, PFS End Points in Pretreated KRAS G12C–Mutated CRC
3
Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma
4
FDA Issues CRL to Orviglance for Liver Metastasis Imaging in Patients With Severe Kidney Impairment
5